Skip to main content
SP5007,745.06-0.52%DOW53,459.78-0.51%NASDAQ26,644.91-0.32%BTC$64,242.00+1.10%ETH$1,899.48+0.06%GOLD$4,451.10-0.51%OIL$84.32+0.69%
Smart Investors Daily
Sign InSign Up Free
Bavarian Nordic A/S logo

OTC · BVNRY

Bavarian Nordic A/S

Healthcare · Biotechnology

$9.64

Up+$0.10 (+1.03%)

Updated Aug 18, 2026, 12:37 PM

SID Score

5.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.34B
P/E ratio
6.19
Dividend yield
0.00%
52-week range
— – —
Volume
112
Avg. volume
3.87K

Price performance

BVNRY price history

1M range · 0 trading sessions · Daily adjusted prices

BVNRY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest BVNRY news

The latest Smart Investors Daily articles mentioning BVNRY.

Stock researchCompany · Overview

BVNRY research

Overview

Company profile and research snapshot.

Company profile

BAVARIAN NORDIC R/I S/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
BVNRY recent ratings
DateFirmRatingTarget
May 18, 2026JEFFERIESBuy—
May 12, 2026DNB CARNEGIEBuy—
May 7, 2026NYKREDIT MARKETSHold—
Feb 27, 2026NYKREDIT MARKETSHold—
Feb 16, 2026DNB CARNEGIEBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 18, 2026

Monkeypox Market Competitive Landscape 2026: Comprehensive Insights About 8+ Companies and 10+ Drugs

Emerging opportunities in the monkeypox treatment and prevention market include innovative vaccine developments by companies such as Bavarian Nordic, BioNTech, and Moderna. The focus is on mRNA-based vaccines and modified vaccines, with numerous clinical trials and strategic collaborations underway to enhance public health responses globally.Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Monkeypox - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The "Monkeypox

Yahoo · Feb 18, 2026

Bavarian Nordic Receives USD 22.5 Million Contract for its Mpox and Smallpox Vaccine from the Government of Canada

COPENHAGEN, Denmark, February 18, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced a new order valued at USD 22.5 million from the Public Health Agency of Canada (PHAC) for the Company’s mpox and smallpox vaccine, MVA-BN®. This order, awarded under the existing 10-year contract framework established with PHAC in 2022, will ensure manufacturing of bulk vaccine product in 2026, with filling and supply of the final drug product to occur later. With this award, Bavarian Nordic has now secured

Yahoo · Feb 16, 2026

A Look At Bavarian Nordic (CPSE:BAVA) Valuation After Recent Mixed Share Price Performance

Bavarian Nordic (CPSE:BAVA) has drawn investor attention after recent share price moves, with a 0.6% decline on the day and mixed returns across the past week, month, and past 3 months. See our latest analysis for Bavarian Nordic. At the current share price of DKK192.0, Bavarian Nordic’s recent 90 day share price return of 5.49% contrasts with a weaker year to date share price return and a 9.78% one year total shareholder return. This suggests momentum has been patchy as investors reassess...

Yahoo · Feb 9, 2026

Bavarian Nordic – Completion of Share Buy-Back Program

COPENHAGEN, Denmark, February 9, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 7, 2026, has now been completed, reaching an aggregate amount of approximately DKK 150 million as planned. This represented the first tranche of a total planned share buy-back of up to DKK 500 million in 2026. Bavarian Nordic will hold the shares bought back as treasury stock, for the purpose of adjusting the capital structure. The progra

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By